AAP
CAPR icon

Arax Advisory Partners’s Capricor Therapeutics CAPR Stock Holding History

Arax Advisory Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-182
Closed -$1.31K – 4143
2025
Q3 		$1.31K Buy
+182
New +$1.34K ﹤0.01% 3196

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's CAPR Position: Q4 2025 in Review

Arax Advisory Partners sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 182 shares — an estimated $1.31K sold.

Arax Advisory Partners first reported a position in CAPR in Q3 2025 and held it in 1 quarter. The position peaked at $1.31K in Q3 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Arax Advisory Partners reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 182 Capricor Therapeutics shares in Q4 2025, an estimated $1.31K.
  • Arax Advisory Partners first reported a position in Capricor Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Capricor Therapeutics position peaked at $1.31K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.